Evidence map›Paper›PMID 38748784›Full record

ArticleCancer research2024

HiChIP-Based Epigenomic Footprinting Identifies a Promoter Variant of UXS1 That Confers Genetic Susceptibility to Gastroesophageal Cancer.

Ansley Gnanapragasam, Eftyhios Kirbizakis, Anna Li, Kyle H White, Katelyn L Mortenson, Juliana Cavalcante de Moura, Wajih Jawhar, Yifei Yan, Reilly Falter, Colleen Russett and 9 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ansley Gnanapragasam *The Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0009-0001-6275-5033
Eftyhios Kirbizakis *The Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0001-5512-261X
Anna LiThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0009-0009-3498-4603
Kyle H WhiteThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0009-0009-0936-797X
Katelyn L MortensonDepartment of Experimental Medicine, McGill University, Montreal, Canada.ORCID 0000-0002-4239-4840
Juliana Cavalcante de MouraThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0009-0009-2320-0121
Wajih JawharThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0002-2724-6401
Yifei YanThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0003-2223-2569
Reilly FalterDepartment of Experimental Medicine, McGill University, Montreal, Canada.ORCID 0009-0006-5644-3080
Colleen RussettThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0009-0001-1749-6650
Betty GianniasThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0003-4786-102X
Sophie Camilleri-BroëtDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.ORCID 0000-0002-3453-636X
Nicholas BertosThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0001-5466-6076
Jonathan Cools-LartigueThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0002-3607-6889
Livia GarziaThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0002-5016-0753
Veena SangwanThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0002-0951-5997
Lorenzo FerriThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0003-3275-2584
Xiaoyang ZhangDepartment of Experimental Medicine, McGill University, Montreal, Canada.ORCID 0000-0002-0031-0290
Swneke D BaileyThe Cancer Research Program, Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, Canada.ORCID 0000-0003-3778-8391

Funding

CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastomaR01CA255369 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GARZIA, LIVIA, TAYLOR, MICHAEL D. · 2021 to 2025
$3.9M
University of Utah Genetics Training ProgramT32GM141848 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI GOLIC, KENT G, GRUNWALD, DAVID J. · 2021 to 2025
$2.9M
Cancer Research Society (CRS)Institute of Cancer Research (IC)NCI NIH HHS R01 CA255369NIGMS NIH HHS T32 GM141848
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) have identified more than a hundred single nucleotide variants (SNV) associated with the risk of gastroesophageal cancer (GEC). The majority of the identified SNVs map to noncoding regions of the genome. Uncovering the causal SNVs and genes they modulate could help improve GEC prevention and treatment. Herein, we used HiChIP against histone 3 lysine 27 acetylation (H3K27ac) to simultaneously annotate active promoters and enhancers, identify the interactions between them, and detect nucleosome-free regions (NFR) harboring potential causal SNVs in a single assay. The application of H3K27ac HiChIP in GEC relevant models identified 61 potential functional SNVs that reside in NFRs and interact with 49 genes at 17 loci. The approach led to a 67% reduction in the number of SNVs in linkage disequilibrium at these 17 loci, and at 7 loci, a single putative causal SNV was identified. One SNV, rs147518036, located within the promoter of the UDP-glucuronate decarboxylase 1 (UXS1) gene, seemed to underlie the GEC risk association captured by the rs75460256 index SNV. The rs147518036 SNV creates a GABPA DNA recognition motif, resulting in increased promoter activity, and CRISPR-mediated inhibition of the UXS1 promoter reduced the viability of the GEC cells. These findings provide a framework that simplifies the identification of potentially functional regulatory SNVs and target genes underlying risk-associated loci. In addition, the study implicates increased expression of the enzyme UXS1 and activation of its metabolic pathway as a predisposition to gastric cancer, which highlights potential therapeutic avenues to treat this disease. Significance: Epigenomic footprinting using a histone posttranslational modification targeted 3D genomics methodology elucidates functional noncoding sequence variants and their target genes at cancer risk loci.

Indexed as

EpigenomicsEsophageal NeoplasmsGenetic Predisposition to DiseaseGenome-Wide Association StudyPolymorphism, Single NucleotidePromoter Regions, GeneticStomach NeoplasmsCell Line, TumorHistonesHumansHistones

Identifiers

PMID38748784
PMCPMC11247317

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.